A.n.n.
@fireflyann
volunteer #CRCSM librarian
#BRAF & #NRAS FB grps
Stage 4 CRC Support & Colon Cancer Stars
trials Stage 2/3 pts
https://t.co/48vU5493pH
ID:46803856
https://www.facebook.com/groups/208490666601307/ 13-06-2009 02:16:26
18,8K Tweets
1,4K Followers
3,2K Following
#TumorBoardTuesday Mike Pishvaian Integrity CE Dr. Shubham Pant PanCAN Lustgarten Foundation Kevan Shokat NEJM UCSF Helen Diller Family Comprehensive Cancer Ctr KRASKickers 15.5/17 #TumorBoardTuesday
🔑 takeaways:
✅Mutant KRAS is now 🎯 in multiple ways
G12C, G12D specific inhib
‼️Pan G12 mutant inhib
Combos w EGFRi & maybe IO may deliver even better responses--more trials needed. Will we need other combos to overcome harsh microenvironment?
#TumorBoardTuesday Mike Pishvaian Integrity CE Dr. Shubham Pant PanCAN Lustgarten Foundation Kevan Shokat NEJM UCSF Helen Diller Family Comprehensive Cancer Ctr KRASKickers 14/17 #TumorBoardTuesday
Mini 🐦orial 10👨🏽🏫
Totally different MOA
RMC 6236 is like a GLUE
Sticks one protein, cyclophilin A, directly onto GTP bound (active) mKRAS.
Similar strat also being used to target KRAS G12C!
The result in PDAC:
Phase I- ORR 20% w some ongoing responses
#TumorBoardTuesday Mike Pishvaian Integrity CE Dr. Shubham Pant PanCAN Lustgarten Foundation Kevan Shokat NEJM UCSF Helen Diller Family Comprehensive Cancer Ctr KRASKickers 11/17 #TumorBoardTuesday
👨🏽🏫Mini Tweetorial 7👨🏽🏫
What about the rest of the (more common) KRAS mutations?
Lots of work ongoing now, including inhibitors targeting other muts, including more common mutations found in #PDAC
🔹G12D specific
🔹Pan exon 12
🔹KRAS “on” inhibitors
#TumorBoardTuesday Mike Pishvaian Integrity CE 5/17 #TumorBoardTuesday
👨🏽🏫Mini Tweetorial 1👨🏽🏫
🧬RAS mutation drives 90+% of #PDAC
Most common mutation is #KRAS G12D or G12V, but a minority of patients have G12C (~3%)
💡In non-RAS mutated disease, higher probability of a gene fusion event as a driver
pubmed.ncbi.nlm.nih.gov/28810144/
#TumorBoardTuesday
🏃We are gaining ground in the chase for the most elusive🎯in cancer💜
📢Join us Tuesday, 03/26/2024 at 8PM ET as Mike Pishvaian & Johnathan Ebben MD, PhD🗣️KRAS targeted therapy as a treatment for #PancreaticCancer
#DidYouKnow that patients with #rectalcancer who have enlarged lateral #lymphnodes have a higher risk of lateral local recurrence?
A new study has determined the prognostic value of LLN size and malignant features in advanced rectal cancer.
Learn more: buff.ly/4cwfIMG
Cardiff Oncology will present 5 posters at #AACR24 . They offer an overview of onvansertib's potential in RAS-mutant & RAS-wild type #mCRC , #smallcelllungcancer & #ovariancancer .
For more details, visit ow.ly/lwot50QNLfP
Full abstracts are on AACR Online Program.